Actively Recruiting
Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction
Led by The Affiliated Hospital of Qingdao University · Updated on 2025-08-19
20
Participants Needed
1
Research Sites
73 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective cohort study will enroll 20 patients clinically diagnosed with first-time acute myocardial infarction (AMI) who underwent interventional procedures (including percutaneous coronary intervention \[PCI\] and balloon angioplasty) at the Affiliated Hospital of Qingdao University. Patient data, including routine blood and urine tests, blood biochemistry, electrocardiograms (ECG), imaging studies, and interventional procedure records, will be collected to assess eligibility for enrollment. The study procedures include patient screening and enrollment, obtaining informed consent, baseline assessment (including medical history, laboratory tests, ECG, etc.), an ¹⁸F-Pentixafor PET/MR examination, and follow-up. Images will be blindly assessed by at least two specialized physicians from the Radiology and Nuclear Medicine departments. The study aims to investigate the utility of ¹⁸F-Pentixafor PET/MR in evaluating coronary microcirculatory function, cardiac function, myocardial viability, myocardial inflammatory response, and the efficacy of interventional therapy in AMI patients post-procedure. Additionally, it will perform risk stratification and prognostic analysis for the enrolled patients.
CONDITIONS
Official Title
Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a clinical diagnosis of first-episode acute myocardial infarction (AMI) who underwent emergency percutaneous coronary intervention (PCI).
- Complete baseline clinical data available.
- Baseline cardiac magnetic resonance (CMR) examinations performed within 7 days after PCI.
- Follow-up CMR completed at 6 months post-procedure.
You will not qualify if you...
- Severe cardiac decompensation (Killip class 4) or clinically unstable conditions.
- Coexisting valvular heart disease, congenital heart disease, pulmonary hypertension, cardiomyopathy, or persistent atrial fibrillation affecting heart assessments.
- Prior history of myocardial infarction or coronary revascularization (PCI or CABG).
- Severe systemic diseases including hematologic disorders, malignancies, rheumatic/autoimmune diseases, or severe liver or kidney failure.
- Contraindications to cardiac magnetic resonance imaging (e.g., claustrophobia, pacemaker).
- Pregnant, breastfeeding, or women of childbearing potential without effective contraception.
- Sexually active individuals of reproductive age unwilling to use reliable contraception.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China, 266003
Actively Recruiting
Research Team
P
Pei Nie, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here